US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kurv Yield Premium Strategy Tesla (TSLA) ETF

19.95

+0.67003.48%

Post-market: 19.950.00000.00%17:42 EDT

Volume:62.34K

Turnover:1.24M

Market Cap:20.55M

PE:- -

High:20.27

Open:19.61

Low:19.61

Close:19.28

Loading ...

Overview Company News Filings

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Press Release: Harbour BioMed Reports Full Year 2024 Financial Results

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Kelun Pharmaceutical Gives Windward Bio Worldwide Commercial Rights for Anti-thymic Drug

MT Newswires Live

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TSLP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TSLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":19.95,"timestamp":1746820800000,"preClose":19.28,"halted":0,"volume":62340,"hourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"delay":0,"floatShares":1030000,"shares":1030000,"eps":0,"marketStatus":"Market Closed","change":0.67,"latestTime":"05-09 16:00:00 EDT","open":19.61,"high":20.2678,"low":19.61,"amount":1243938.9741,"amplitude":0.034118,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":19.28,"sharesOutstanding":1030000,"nav":19.33,"aum":19909900,"dividendRate":0.445614,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":19.55,"preClose":19.28,"latestTime":"08:30 EDT","volume":52,"amount":1018.600076,"timestamp":1746793848244},"postHourTrading":{"tag":"盘后","latestPrice":19.95,"preClose":19.95,"latestTime":"17:42 EDT","volume":22,"amount":444.2875,"timestamp":1746826945059},"volumeRatio":1.8028729456987524,"impliedVol":0.418,"impliedVolPercentile":0.8},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TSLP\",,,,,undefined,":{"symbol":"TSLP","floatShares":1030000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8028729456987524,"shares":1030000,"dividePrice":8.89,"high":20.2678,"amplitude":0.034118,"preClose":19.28,"low":19.61,"week52Low":15.36,"pbRate":"--","week52High":34.2895,"institutionHeld":0,"latestPrice":19.95,"eps":0,"divideRate":0.445614,"volume":62340,"delay":0,"ttmEps":0,"open":19.61,"prevYearClose":30.27,"prevWeekClose":19.9339,"prevMonthClose":19.63,"prevQuarterClose":18.48,"fiveDayClose":19.9339,"twentyDayClose":17.53,"sixtyDayClose":24.54},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TSLP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532683802","title":"AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532683802","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532683802?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:01","pubTimestamp":1746129660,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen  today announced financial results for the first quarter of 2025.\"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects,\" said Robert A. Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024.Product sales grew 11%, primarily driven by 14% volume growth, partially offset by 6% lower net selling price. U.S. sales grew 14%.Fourteen products delivered at least double-digit sales growth in the first quarter, includingRepatha , BLINCYTO , TEZSPIRE , EVENITY , TAVNEOS  and UPLIZNA .Non-GAAP EPS increased 24% from $3.96 to $4.90, driven by higher revenues, partially offset by higher operating expenses.Repatha  sales increased 27% year-over-year to $656 million in the first quarter, pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2025-200100246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","LU1057294990.SGD","SLE","IE0009355771.USD","LU0122379950.USD","LU2242652126.USD","LU0109394709.USD","GIPR","BK4160","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4188","LU2089984988.USD","BK4233","BK4585","IE00BJT1NW94.SGD","TSLP","BK4205","IE0002141913.USD","LU0058720904.USD","LU2242646821.SGD","BK4200","PN","TCS","BK4599","LU1061106388.HKD","LU0320765992.SGD","LU1023059063.AUD","SG9999001440.SGD","BK4096","BK4588","LU2112291526.USD","BK4533","LU0889565916.HKD","BK4566","MPA","MTA","IE00BFTCPJ56.SGD","BK4534","BK4139","BK4211","LU0868494617.USD","AMGN","FCF","TCI","BK4581","LU0289739699.SGD","LU1983299246.USD","BK4077"],"gpt_icon":0},{"id":"2529637228","title":"Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2529637228","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529637228?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:59","pubTimestamp":1745319540,"startTime":"0","endTime":"0","summary":"- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -. WAYNE, Pa, April 22, 2025  -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets thymic stromal lymphopoietin  and interleukin-4 receptor  that blocks both the upstream TSLP receptor signal transduction and downstream IL-4R activation which inhibits both IL-4 and IL-13 signaling, thereby inhibiting this central proinflammatory pathway and potentially offering enhanced efficacy through dua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aclaris-therapeutics-secures-u-food-105900381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","ATI","IE00B7SZL793.SGD","LU2065731478.USD","TSLP","IE00B66KJ199.SGD","BK4007","IE0031619046.USD","LU1878469433.USD","BK4006","ACRS"],"gpt_icon":0},{"id":"2523191987","title":"Press Release: Harbour BioMed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191987?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed,  commented: \"The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.Compared to 2023, the company's revenue sustainability has continued to improve. Annual recurring revenue in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4099","03160","BK1574","BK4585","BK4604","R","BK4022","BK4588","02142","BK4555","SD","BK1161","BK4232","TSLP","BK1583","TM"],"gpt_icon":0},{"id":"2516635849","title":"Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516635849","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516635849?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:01","pubTimestamp":1741006860,"startTime":"0","endTime":"0","summary":"- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March  03, 2025  (GLOBE NEWSWIRE) -- Celldex Therapeutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035595/24180/en/Celldex-Therapeutics-Presents-Positive-Preclinical-Data-from-Inflammatory-Bispecific-Antibody-Program-CDX-622-at-AAAAI-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139","CDX","TSLP"],"gpt_icon":0},{"id":"2516684183","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516684183","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516684183?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:05","pubTimestamp":1740999900,"startTime":"0","endTime":"0","summary":"Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035381/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4139","BK4218","BK4097","APGE","PRGS","BK4023","LU1169590202.USD","TSLP","PK","BK4181","LU2065732104.USD","PD"],"gpt_icon":0},{"id":"2516564150","title":"POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2516564150","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516564150?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery. Data Published in NEJM and Presented at AAAAI/WAO 2025. THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen  and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 The data were published today in the New England Journal of Medicineand were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego.1,2. \"Chronic rhinosinusitis with nasal polyps is a recurrent condition often requiring repeat courses of systemic corticosteroids, even for patients on currently available biologics, and can require repeat surgeries,\" said Jay Bradner, M.D., executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","BK4503","LU1242518857.USD","BK4535","LU1023059063.AUD","LU1061106388.HKD","BK4581","BK4588","LU0320765992.SGD","SG9999004360.SGD","BK4599","SG9999002620.SGD","LU0516422952.EUR","IE0002141913.USD","LU0261945553.USD","LU0737861269.HKD","SG9999013478.USD","LU2045819591.USD","SG9999013460.SGD","LU0572940350.SGD","BK4585","SG9999001440.SGD","SGXZ58947870.SGD","LU1242518931.SGD","IE00BJJMRZ35.SGD","LU2242652126.USD","TSLP","SG9999006266.SGD","IE0034224299.USD","LU0264606111.USD","LU0516423091.SGD","SG9999002414.USD","LU0532188223.SGD","LU1983299246.USD","FL","IE00B4R5TH58.HKD","LU0210637038.USD","AMGN","LU2242646821.SGD","SG9999013486.USD","TSS","SG9999002406.SGD","LU0889565916.HKD","LU0289739699.SGD","SG9999014484.SGD","BK4534","LU0251143029.SGD","LU0048573645.USD","LU0572939691.SGD"],"gpt_icon":1},{"id":"2516168564","title":"Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168564","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516168564?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps. WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI/WAO 2025. WILMINGTON, Del., March 01, 2025----Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE  significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego, CA.1,2. Statistically significant and clinically meaningful improvements were observed across all key secondary outcomes assessed in the overall tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-phase-iii-223000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","III","LU2236285917.USD","SG9999006266.SGD","SG9999002679.SGD","LU0532188223.SGD","BK4554","BK4585","LU0889565916.HKD","SG9999002414.USD","SG9999002620.SGD","LU0516422366.SGD","SG9999014484.SGD","LU0516422952.EUR","LU0979878070.USD","IE0034224299.USD","BK4568","LU1242518857.USD","SG9999014492.USD","TSLP","LU0048573645.USD","LU0516422440.USD","LU2456880835.USD","SG9999013478.USD","LU1242518931.SGD","LU1829250122.USD","LU0516423091.SGD","LU0737861269.HKD","BK4134","SG9999004360.SGD","LU0516423174.USD","LU2045819591.USD","LU2417539215.USD","SG9999002406.SGD","LU0572939691.SGD","LU0261945553.USD","BK4551","SGXZ58947870.SGD","LU0251143029.SGD","SG9999013486.USD","SG9999013460.SGD","SG9999002604.SGD","AZN","TSS","SG9999001135.SGD","BK4566","FL","BK4503","LU0320765992.SGD"],"gpt_icon":1},{"id":"2514712330","title":"Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514712330","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514712330?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:01","pubTimestamp":1740690060,"startTime":"0","endTime":"0","summary":"Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentPhase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3034268/24180/en/Celldex-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","TSLP","SD","CLDX","PN","BK4139"],"gpt_icon":0},{"id":"2503343081","title":"Kelun Pharmaceutical Gives Windward Bio Worldwide Commercial Rights for Anti-thymic Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2503343081","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503343081?lang=en_us&edition=fundamental","pubTime":"2025-01-13 11:20","pubTimestamp":1736738419,"startTime":"0","endTime":"0","summary":"Sichuan Kelun Pharmaceutical (SHE:002422), through its subsidiaries, granted Switzerland-based Windward Bio the right to commercialize a anti-thymic stromal lymphopoietin worldwide, according to a Mon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSLP"],"gpt_icon":0},{"id":"2490094414","title":"Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094414","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094414?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:00","pubTimestamp":1733832000,"startTime":"0","endTime":"0","summary":"Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus mon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994371/0/en/Apogee-Therapeutics-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-of-APG333-its-Novel-Half-Life-Extended-TSLP-Antibody-for-the-Treatment-of-Respiratory-and-Broader-I.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4585","LU1861559042.SGD","BK4503","BK4581","BK4551","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","BK4528","IE0002270589.USD","BK4554","APGE","IE00BHPRN162.USD","BK4106","BK4181","TSLP","BK4227","BK4218","LU1861558580.USD"],"gpt_icon":0},{"id":"2484115844","title":"Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115844","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115844?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:01","pubTimestamp":1732107660,"startTime":"0","endTime":"0","summary":"HAMPTON, N.J., Nov.  20, 2024  (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in healthy ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984404/24180/en/Celldex-Announces-First-Patient-Dosed-in-Phase-1-Healthy-Volunteer-Study-of-CDX-622-a-Bispecific-Antibody-for-the-Treatment-of-Inflammatory-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDX","BK4139","CLDX","TSLP"],"gpt_icon":0},{"id":"2484067879","title":"Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2484067879","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484067879?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:50","pubTimestamp":1731937800,"startTime":"0","endTime":"0","summary":"Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit sales royalty. Aclaris Therapeutics will be responsible for development and commercialization of BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide . Under the terms of the agreement, Biosion shall receive over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials. Biosion shall also receive 19.9% shares of common stock of Aclaris Therapeutics. Additional regulatory and sales milestone payments exceed $900M with tiered low-to-mid single digit royalty based upon a percentage of annual net sales.\"This strategic transaction brings together Biosio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VI.zAJkLvR8QsLM.b8VCuQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/88961afa50383a217034358ccd97e5dd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VI.zAJkLvR8QsLM.b8VCuQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/88961afa50383a217034358ccd97e5dd"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biosion-announces-exclusive-global-license-135000512.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biosion-announces-exclusive-global-license-135000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TSLP","ACRS"],"gpt_icon":1},{"id":"2484462273","title":"Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2484462273","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484462273?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:10","pubTimestamp":1731935400,"startTime":"0","endTime":"0","summary":"- Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/18/2982759/37216/en/Aclaris-Therapeutics-Announces-Exclusive-Global-License-Agreement-with-Biosion-Inc-adding-Potential-Best-in-Class-Biologics-Assets-to-Pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","BK4007","ACRS"],"gpt_icon":1},{"id":"2482708280","title":"Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482708280","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482708280?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile. On track to report Phase 2 Part A data for APG777 in 2H 2025, interim Phase 1 data for APG808 in 4Q 2024 and interim Phase 1 data for APG990 in 1H 2025. APG333 development candidate selected and accelerating initiation of Phase 1 in late 2024 or early 2025; potential to offer best-in-class combination efficacy across multiple respiratory indications. Plans advancing for combination studies, starting with the first clinical trial of the APG777 and APG990 combination for the treatment of AD in 2025. $754 million cash, cash equivalents and marketable securities with runway into 2028. Virtual R&D Day to be held December 2, 2024 at 10am ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4551","LU1169590202.USD","TSLP","IE0002270589.USD","BK4528","BK4581","PK","BK4106","PRGS","BK4554","BK4139","BK4503","BK4227","BK4218","IE00B19Z3581.USD","BK4023","APGE","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","IE00BHPRN162.USD","PD","LU1861558580.USD","LU1861559042.SGD","BK4588","LU2065732104.USD","LU1169589451.USD","BK4097"],"gpt_icon":0},{"id":"2481092179","title":"TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2481092179","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481092179?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:00","pubTimestamp":1731067200,"startTime":"0","endTime":"0","summary":"TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo. WILMINGTON, Del., November 08, 2024----Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps  showed that AstraZeneca and Amgen’s TEZSPIRE  demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo.Dr. Joseph Han, Vice Chair of Rhinology & Endoscopic Sinus and Skull Base Surgery, and Allergy, Otolaryngology-Head and Neck Surgery, Eastern Virginia Medical School, US, and co-primary investigator in the trial, said: \"Chronic rhinosinusitis with nasal polyps negatively impact patients’ daily lives with obstructions leading to disturbances in smell, taste and sleep as well as pain and fatigue. The impressive data from the WAYPOINT trial demonstrate tezepelumab’s potential as a n","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.x6IuLbiwiKzO31v0vj8VQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7999e1972a9dd88681317447dec39927","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.x6IuLbiwiKzO31v0vj8VQ--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7999e1972a9dd88681317447dec39927"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tezspire-met-both-co-primary-120000955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSLP","LU0320765992.SGD","BK4007","BK4134","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","BK4568","LU2462157665.USD","BK4585","BK4588","III","LU0889565916.HKD","LU2417539215.USD","BK4094","AZN","LU0109394709.USD","FL"],"gpt_icon":0},{"id":"2481314140","title":"TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2481314140","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481314140?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:00","pubTimestamp":1731049200,"startTime":"0","endTime":"0","summary":"Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo. THOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen  and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps . The trial demonstrated patients treated with TEZSPIRE  had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability ofTEZSPIREin the trial were consistent with the known profile of the medicine.\"Patients diagnosed with nasal polyps continue to experience significant burden including repeat surgeries and frequent treatment with high doses of oral corticosteroids, which are associated with serious systemic side effects,\" said Dr. Brian Lipworth, Professor of Allergy and Pulmonology, Scottish Centre for Respiratory Research, and Tayside Rhinology Ear, Nose and Throat Clin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/tezspire-met-both-co-primary-070000793.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tezspire-met-both-co-primary-070000793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4094","FOR","LU1023059063.AUD","LU1061106388.HKD","BK4139","LU0122379950.USD","BK4581","BK4588","LU0320765992.SGD","LU0058720904.USD","LU1989772840.SGD","IE0002141913.USD","LU1057294990.SGD","LU0868494617.USD","LU2112291526.USD","BK4585","SG9999001440.SGD","IE0009355771.USD","BOTH","BK4024","IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1989771016.USD","LU2242652126.USD","TSLP","LU1983299246.USD","MET","LU0109394709.USD","FL","IE00B4R5TH58.HKD","BK4162","AMGN","LU2242646821.SGD","BK4533","LU1496350502.SGD","LU1571399168.USD","LU1989772923.USD","LU0889565916.HKD","BK4566","LU0289739699.SGD","BK4534"],"gpt_icon":0},{"id":"2481028905","title":"Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2481028905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481028905?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/07/2976499/0/en/Upstream-Bio-Reports-Third-Quarter-2024-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","BK4218","LU1169590202.USD","LU1169589451.USD","PK","IPO","PD","BK4181","BK4023"],"gpt_icon":0},{"id":"2481908954","title":"Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481908954","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481908954?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:01","pubTimestamp":1730926860,"startTime":"0","endTime":"0","summary":"Enrollment continues in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under developmentAll primary and secondary endpoints met with high statistical significance in global Phase 2 CIndU ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2976017/24180/en/Celldex-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SD","BK4213","TSLP","CLDX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TSLP\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"TSLP","amount":0.55,"announcedDate":"2025-05-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-07","defaultRemindTime":1746624600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-08","payableDate":"2025-05-07","currency":"USD","dateTimestamp":1746590400000,"payDate":"2025-05-08"},{"date":"2025-04-02","symbol":"TSLP","amount":0.55,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-02","defaultRemindTime":1743600600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-02","currency":"USD","dateTimestamp":1743566400000,"payDate":"2025-04-03"},{"date":"2025-03-05","symbol":"TSLP","amount":0.7,"announcedDate":"2025-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-05","defaultRemindTime":1741185000000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-06","payableDate":"2025-03-05","currency":"USD","dateTimestamp":1741150800000,"payDate":"2025-03-06"},{"date":"2025-02-05","symbol":"TSLP","amount":1,"announcedDate":"2025-02-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-05","defaultRemindTime":1738765800000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-06","payableDate":"2025-02-05","currency":"USD","dateTimestamp":1738731600000,"payDate":"2025-02-06"},{"date":"2025-01-23","symbol":"TSLP","amount":1.3,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-23","defaultRemindTime":1737642600000,"name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-24","payableDate":"2025-01-23","currency":"USD","dateTimestamp":1737608400000,"payDate":"2025-01-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TSLP\",market:\"US\",,,undefined,":[{"executeDate":"2023-11-22","recordDate":"2023-11-24","paymentDate":"2023-11-27","value":0.5775,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-22","value":0.6664,"currency":"USD"},{"executeDate":"2024-01-24","recordDate":"2024-01-25","paymentDate":"2024-01-26","value":0.5555,"currency":"USD"},{"executeDate":"2024-02-21","recordDate":"2024-02-22","paymentDate":"2024-02-23","value":0.313,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-22","value":0.5189,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TSLP\",market:\"US\",delay:false,,,undefined,":{}}}